



## Spectros Corporation Year-To-Date Oximeter Sales Revenue Up 51% in First Half of 2011

PORTOLA VALLEY, Calif., July 29, 2011 /PRNewswire/ -- Spectros, developer and manufacturer of the T-Stat VLS Tissue Oximeter announces its success in the reconstructive plastic surgery market.

Spectros Corporation announced today that 2011 year-to-date sales revenue rose 51% (year-over-year) over the similar period in 2010. This continues the third year in a row for double-digit revenue growth for Spectros since the current T-Stat Tissue Oximeter product line was launched in 2008.

"This growth sends a clear signal that the market is embracing the Spectros state-of-the-art broadband VLS tissue oximetry," notes CFO John Bagnatori.

Spectros T-Stat® and Continuum® Tissue Oximeters are the only broadband tissue oximeters on the market in the U.S. and Europe. T-Stat® and Continuum® compete in the marketplace with INVOS® oximeters marketed by Covidien. An expanded array of probes, including Continuum® broadband cerebral probes currently being readied for manufacturing, pending FDA approval and release anticipated over the next year.

### About Spectros

Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. T-Stat was the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue, and remains the only commercially-available tissue oximeter that utilizes state-of-the-art broadband spectroscopy. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.

Spectros also develops molecular diagnostic tools for breast and prostate cancer, including ProstaFluor® contrast agents, currently entering phase I/II clinical trials supported by the National Cancer Institute. (Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment. Certain applications described above have not been reviewed by the FDA or European agencies, and are therefore labeled "for investigational use only." T-Stat and Continuum are trademarks of Spectros. INVOS is a trademark of Somanetics and Covidien. FORE-SIGHT is a trademark of CAS Medical).

*For further information, visit [www.spectros.com](http://www.spectros.com).*

*SOURCE Spectros*

*Media Contact: Ms. Elizabeth van Thillo-Rohlf of Spectros, +1-650-529-2865, [info@spectros.com](mailto:info@spectros.com)*